Literature DB >> 11128911

Surgical management of advanced ovarian cancer.

D Nunns1, P Symonds, D Ireland.   

Abstract

Surgery is an essential part of the management of patients presenting with ovarian cancer. Diagnosis, staging, and therapy can be carried out at the time of laparotomy. Unfortunately, the disease often presents at an advanced stage and the outlook for patients is poor with an overall 5-year survival rate of 23%. This review focuses on the surgical management of advanced ovarian cancer and focuses on both primary, secondary, and intervention debulking surgery.

Entities:  

Mesh:

Year:  2000        PMID: 11128911     DOI: 10.1097/00006254-200012000-00005

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  3 in total

1.  The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.

Authors:  Zhiguang Zhao; Anqi Zhang; Yuan Zhao; Junmiao Xiang; Danyang Yu; Zongwen Liang; Chaoyi Xu; Qiong Zhang; Jianmin Li; Ping Duan
Journal:  Biosci Rep       Date:  2018-06-21       Impact factor: 3.840

2.  No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects.

Authors:  Anqi Zhang; Ting-Yan Shi; Yuan Zhao; Junmiao Xiang; Danyang Yu; Zongwen Liang; Chaoyi Xu; Qiong Zhang; Yue Hu; Danhan Wang; Jing He; Ping Duan
Journal:  Oncotarget       Date:  2017-11-21

3.  Efficacy of weekly paclitaxel for the treatment of advanced ovarian cancer: A protocol for systematic review and meta-analysis.

Authors:  Dong-Xu Zhao; Ping Chen; Cui-Hong Su; Yan-Yan Zhao; Li-Dan Sun; Hong He; Xiao-Na Feng
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.